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ABSTRACT
Aim: The aim of this study is to summarize the outcomes of transfers of mosaic embryos, which were
classified according to guidelines and in strong collaboration of reproductologists, clinical geneticists and
patients approved as suitable for transfer.
Material and Methods: Retrospective data were collected from 70 patients from a private IVF center to
whom embryos with mosaic changes in chromosomal material were transferred from 2015 to 2019.
Results and Conclusion: Implantation outcomes and continuing pregnancies showed slight differences,
when compared to fully normal embryos. Artifacts have to be differentiated from undeniable aberrations,
and correct interpretation of results must be done with following patient counselling and prenatal testing
if necessary.
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Introduction
Preimplantation genetic testing for aneuploidy (PGT-A) is devel-
oped as one of the opportunities to achieve better results in IVF
pregnancies. The great challenge with this method is interpret-
ation of results of embryos when mosaic aneuploidies are
observed. Full aneuploidies in the embryo are mainly meiotic
and are the result of improper chromosome segregation in the
development of gametes [1]. As second event mitotic errors are
possible in embryo growth and results in chromosomally mosaic
organism [2]. Chromosomal mosaicism is the appearance of dif-
ferent chromosomally distinct cell lines in an embryo or devel-
oped individual. The mosaicism might have adverse effects on
the phenotype if present in ICM (inner cell mass) of the embryo.
Aberrant cells tend to become apoptotic or move to trophecto-
derm, which later forms the placenta, and in such manner, the
embryo performs self-correction. Various karyotypes of placental
cells might cause adverse results of pregnancy, for example, fetal
growth restriction or placental insufficiency [3]. Mosaicism can
be divided into general and confined form. General mosaicism
appears as a presence of mosaic cells in both, placenta and fetus
[3]. Confined mosaicism of cells is defined as aberrant cells in
outer tissues of embryo, while the fetal cells are fully diploid [4].
Different testing approaches, like FISH (fluorescent in situ
hybridization), aCGH (array comparative genomic hybridiza-
tion), or NGS (next generation sequencing) have approved the
heterogeneity of chromosomal material [5]. It is complicated to
distinguish artifacts from true aberrations in segmental chromo-
some rearrangements due to various methodological limitation,
technical biases, and quality of TE biopsy. Several guidelines
have been developed to summarize available information for dif-
ferent possible chromosomal testing results [6,7]. Using these
guidelines, when making decisions of ambiguous PGT-A results,
allows to choose embryos which have high possibility to develop
into a healthy child and avoid undesirable events in case of preg-
nancy. The aim of this study is to summarize the results of
transfers of mosaic embryos, which are classified according to
guidelines and in strong collaboration of reproductologists, clin-
ical geneticists, and patients approved as suitable for transfer.
Methods
Patients
Results were collected from 70 patients from a private IVF cen-
ter, to whom embryos with mosaic changes in chromosomal
material were transferred from 2015 to 2019. As a control group
patients with 168 transfers of euploid embryos were selected. All
patients have signed informed consents and approved the use of
their anonymized data. Data collection was done following the
principles of the Declaration of Helsinki.
Patients were classified in groups according to age: ‘below
advanced maternal age’ (<35 years old) and ‘advanced maternal
age’ (>35 years old). Patients from the subject group were div-
ided into subgroups according to the method used for PGT-A –
aCGH and NGS.
To exclude chromosomal aberrations in patients, parental kar-
yotyping was performed using classical G band cytogenetic
approach according to ISCN (The International System for
Human Cytogenetic Nomenclature) criteria.
In addition, endometrial receptivity test (ERA, Igenomix) was
done for female patients to exclude endometrial receptivity shift.
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IVF and embryo biopsy procedure
Patients underwent controlled ovarian stimulation with agonists
and antagonists using standard protocols. The dosages were cal-
culated after the evaluation of ovarian reserves and AMH (anti-
Mullerian hormone) values. When follicles reached a size of
18–20mm in diameter, the trigger was injected. Oocytes were
retrieved 36 h after injection, and ICSI (intracytoplasmic sperm
injection), in some cases PICSI (Physiological intracytoplasmic
sperm injection), for cells, reached MII state, was performed.
The sperm from male patients was selected using discontinuous
density gradient according to WHO laboratory manual for the
examination and processing of human semen. Cultivation of
embryos was for 5–6 days in Embryoscope. When the embryo
reached the blastocyst stage, the embryologist performed hatch-
ing with laser Saturn 5 (Cooper Surgical) and obtained trophec-
todermal cells through the opening in zona pellucida.
Classification of embryo quality was made as follows: ‘low qual-
ity,’ ‘moderate,’ and ‘high quality’ according to quality of inner
cell mass and trophectodermal cells using Gardner and
Schoolcraft criteria. Kitazato vitrification approach was used for
embryo vitrification.
Whole genome amplification (WGA) and chromosomal analysis
PGT-A was done either by aCGH with Illumina 24Sure array
protocol from 2015 to 2017 or by NGS with Illumina VeriSeq
PGS protocol from 2018 to 2019. An analysis was performed
with Bluefuse software. Interpretation of results was made by at
least two molecular geneticists and at least one clinical geneticist.
Chromosomal aberrations were classified according to guidelines:
euploid, low-level mosaic (20–50%), high-level mosaic (50–80%),
aneuploid. A decision regarding transfer was made according to
chromosomes involved and type of aberration (whole chromo-
some versus partial).
Counseling
Transfer of embryo with mosaic aneuploidies was offered to the
patient only in case if there were no euploid embryos for trans-
fer. All patients in the subject group visited reproductologist and
clinical geneticist before the planned transfer. Embryos with
mosaic aberrations were transferred after informed consent.
Transfer day was chosen according to ERA test results to obtain
more successful results.
Statistics
Due to the small number of mosaic embryo cases (n¼ 70), statis-
tical analysis was not performed.
Results
In the subject group, 61% of women (n¼ 43) were in advanced
maternal age (>35 years old), and in 12 cases oocytes were
retrieved from donors (17%). In the control group (n¼ 168),
37% (n¼ 63) patients reached advanced maternal age (>35 years)
during therapy time. In the control group, only 7 oocytes were
obtained from donor follicles (4%). Patients from the subject
group were divided into subgroups according to the method
used for PGT-A. In aCGH ‘below advanced maternal age’ subject
group (<35 years old, n¼ 4, 18%), 49 oocytes and 18 embryos
were retrieved. In aCGH ‘advanced maternal age’ subject group
(>35 years old, n¼ 18, 82%), 198 oocytes and 73 embryos were
obtained. In NGS subject ‘below advanced maternal age’ subject
group (n¼ 15, 32%), 174 oocytes and 61 embryos were obtained,
in ‘advanced maternal age’ subject group (>35 years old, n¼ 33),
316 oocytes and 118 embryos were obtained. From all 70 cases
in subject group, morphology of embryo was defined as ‘high
quality’ in 31% (n¼ 22) cases, 39% (n¼ 27) mosaic embryos
were evaluated as moderate, in 10% (n¼ 7) embryo morphology
was described as ‘very low quality.’ Amongst control group, there
were only 2% (n¼ 3) with morphology defined as ‘low quality,’
44% (n¼ 74) was in moderate morphology group and 54%
(n¼ 91) embryo quality was high (Figure 1). From subject group,
total count of transfers with mosaic embryo was in aCGH group
– 22, and in NGS group – 48.
Thirty-three of detected mosaics included whole chromosome
aneuploidies, 22 of mosaic results were segmental aberrations, in
15 cases chromosomal changes included more than four regions
and were described as complex chaotic chromosomal changes.
Most of the detected aberrations in the subject group were con-
sidered as low-level mosaics. In some cases, repeated testing was
performed to exclude false-positive result due to technical bias,
mosaic level fluctuated in 10% range. In the aCGH group, 50%
(n¼ 11) embryos were diagnosed with whole chromosome aneu-
ploidies; 36% (n¼ 8) were recognized with segmental aberra-
tions; results of 14% (n¼ 3) were described as complex chaotic
chromosomal changes. In the mosaic embryo group, analyzed
with NGS, 47% (n¼ 22) were characterized as whole chromo-
some mosaics; in 30% (n¼ 14) mosaic aberrations included par-
tial regions of chromosomes; in 25% (n¼ 12) changes of
chromosomal material were described as complex chaotic
chromosomal changes.
Implantation outcomes and continuing pregnancies showed
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Figure 1. (A) Comparison of mosaic and euploid embryo morhology. (B)
Comparison of outcomes of mosaic and euploid embryo transfers.
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Biochemical pregnancy rates were 64% in the subject group and
75% in the control group. The clinical pregnancy rate was 46%
and 60% accordingly (Figure 2). The first screening and anomaly
scan with USG was without abnormalities in all cases, where
pregnancy continued.
Comparing results of transfer with mosaic embryos in the
subject group between methods used for PGT-A, the percentage
of biochemical pregnancies in the aCGH group was 59%
(n¼ 13), and in the NGS group, it was 63% (n¼ 30). The clinical
pregnancy rates achieved 45% in the aCGH group (n¼ 10) and
48% in the NGS group (n¼ 23). The livebirth rate in the aCGH
mosaic group was 31% (n¼ 7). The livebirth rate in the NGS
group at this moment is 37% (n¼ 19), and 4 more ongoing
pregnancies at the moment of article writing.
Artifacts
Due to technical biases interpretation of PGT-A analysis is some-
times difficult. Mosaic chromosomal profiles and given embryo sta-
tus can be impacted by faulty amplifications of certain chromosomal
regions. In the subject group, 21% (n¼ 15; 3 in aCGH group, 12 in
NGS group) embryos had low-level complex chaotic chromosomal
changes, that included mosaic deletions of subtelomeric regions.
Repeating mosaic partial aberrations of specific chromosomes are
observed in different embryos not only in the subject group. In the
aCGH group, it was 3 cases with segmental changes in autosome 18.
In the NGS group, there were 13 segmental mosaic cases in different
chromosomes. 50% (n¼ 6) of them included mosaic aberrations in
acrocentric chromosomes. Frequent unreliable cases of mosaic tri-
somy of chromosome 19 are detected, but were not included in the
subject group.
Case descriptions
Six cases, where patient consents were obtained for detailed
description, are summarized in Table 1. In five cases, livebirth
without congenital anomalies was achieved, in one case there is
ongoing pregnancy. In all six cases, pregnancy was achieved after
transfer with mosaic embryo. Each of embryo had different
mosaic chromosomal aberrations.
In case 2, two IVF cycles were performed. In the first IVF
cycle, the patient chose to perform embryo transfer without
Figure 2. (A) aCGH result of the product of conception, case 2. (B) NGS result of the corresponding embryo, case 2.
GYNECOLOGICAL ENDOCRINOLOGY S55
PGT-A, although biopsies of embryos were done. At week 5 she
miscarried. The product of conception was sent to aCGH ana-
lysis, the result showed no chromosomal aneuploidies –
aCGH(1-22,X)x2 (Figure 2(A)). Chromosomal analysis of the
embryo biopsy, used for the transfer, was executed afterward to
exclude possible mosaicism. NGS analysis showed mosaic tri-
somy of autosome 12, seq[GRCh37](12)x2 3 (Figure 2(B)).
This shows the possible impact of mosaic aneuploidies on preg-
nancy continuity. Successful pregnancy in case 2 was achieved
with mosaic embryo after PGT-A analysis was done.
Discussion
Mosaicism of genetic material is described as two or more differ-
ent cell lineages in one organism. This phenomena in PGT-A
genetic analysis by aCGH and NGS sometimes is difficult to rec-
ognize or to distinguish from artifacts because of tissue specifi-
city, technical conditions, or phenotypic variations. In our
subject group, biochemical and clinical pregnancy/livebirth rates
differed only slightly between aCGH and NGS groups. Our
results are similar to those obtained by Yang et al. [8], where
diversities in pregnancies and livebirths did not exceed 10%. The
effect of each mosaic is unique in each case, and it is problematic
to make adequate interpretations and statistically significant
results in the shortage of well-defined genotypes and phenotypes,
and limited subject groups [9]. Embryos, where chromosomal
aberration is derived from meiosis mainly develop as 100% aneu-
ploids. In such cases, the prediction of pregnancy outcome can
be made convincingly [10]. The source for trisomic mosaics is
either of a somatic or meiotic origin. Somatic aneuploidies are
more often, but are excluded by placental tissue and with mar-
ginal clinical result [11]. The consequences of embryo develop-
ment involve many variables – chromosome number, proportion
of abnormal cells, and the location of aberrant cell lineages [12].
Mosaicism of trisomies is present in 1–2% of chorion villus sam-
ples (CVS). In cases of confined chorionic mosaicism (CCM),
pregnancy outcomes are mostly normal, and adverse results arise
from aberrant cells in the fetus or uniparental disomies [13].
We compared embryo implantation and ongoing pregnancy
rates between mosaic and euploid embryos. Our results illustrated
the assumption that conceptions with mosaic embryos can still
lead to successful livebirths, and pregnancy rates are lower, but
still relevant. Almost none of the mosaic aberrations in transferred
embryos from our group exceeded 50% borderline. Lin et al. [14]
demonstrated that mosaics, higher than 50%, still result in live
birth cases, however, miscarriage levels are 25% higher, when
compared to low-level mosaics. The reported case of Kahraman
et al. [15], where healthy offspring with 2% cells with monosomy
of autosome 2 was born, does not exclude the possibility, that
there could be more similar cases after the transfer of mosaic
embryos. The fact, that children are born healthy, only proves that
IVF clinics should do more careful follow-up not only during the
pregnancy, but at the neonatal stage as well. In Case 2, from our
results, mosaic trisomy of autosome 12 was detected in embryo
TE cells, however, the same aberration was not identified in chori-
onic material of POC. All the possibilities of errors were excluded.
Therefore we can discuss the theory about embryo self-correction
[16]. Confined placental mosaicism (CPM) could occur as well in
this case [4]. Very likely abnormal cells from trophectodermal cells
can be eliminated, while abnormal cells in the inner layers stay
and impair the continuing development. There is no evidence
about placental cells passing the basal lamina, therefore the move-
ment could have happened in very early stages of development.
Discrepancies between chorion villi and embryo chromosomal
material are described before. This is caused by isolated non-dis-
junction in trophectodermal cells. Fetal blood is more strictly
linked to chorion than to embryo itself [17]. Despite, when fetal
blood was compared to chorion, 50% results were discordant [18].
Segmental mosaicism is another issue in preimplantation
diagnostics. Zore et al. [19] proved 66% lower birth rates and
22% elevated miscarriage levels in segmental aberrations group.
Sub-chromosomal aberrations are of mitotic origin in 70% cases.
Therefore, positive predictive value for full-chromosome aneu-
ploidies in ICM is higher (97.18% vs 70.8%) [20]. Diagnostics of
segmental chromosomal rearrangements are more problematic
when compared with whole chromosome mosaics and can be
impacted by different reasons, such as confined mosaicism,
WGA artifacts, reciprocal errors, S-phase artifacts, or algorithm
imperfections [21,22]. Victor et al. [23] showed that the type of
mosaicism is the playing factor for implantation – embryos with
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segmental aneuploidies implanted better, when compared with
whole chromosome mosaics.
The quality of the embryo and the following aspect of biopsy
leaves an impact on PGT-A and fertilization outcome. Fiorentino
et al. [24] demonstrated the importance of aneuploidy type,
poorer results of IVF cycles were in cases with complex or seg-
mental mosaic aberrations, when compared with whole chromo-
some aneuploidies. Our clinic experience shows, that the
problematic biopsies arise from the lower grade embryos. If
blastocyst is not separated from zona pellucida, the quality of
inner cell mass and trophectoderm is faulty, cell division is eval-
uated as low, and the cells obtained for biopsy are few and might
be damaged. So, the embryo quality impacts biopsy and following
amplification artifacts in PGT-A result. Such results arise add-
itional risk to reject chromosomally normal embryos. False-posi-
tive mosaics sometimes might be recognized by odd patterns of
probe aberrations – only several probes duplicated/deleted, making
skewed, vague borders, wavy profiles, or frequent aberrations with
usually rare frequency in certain regions. In Case 2, six embryos
were obtained in the second IVF cycle, and four of them exhibited
mosaic deletions of 5p region. After FISH investigation of corre-
sponding regions in both partners, no similar findings were
detected, embryo without mosaic deletion in 5p region was
selected for transfer, to avoid possible impact on the child, if such
event is present in ICM. Here we can consider whether frequent
segmental mosaics are real, or just artifacts because of the PGT-A
method’s imperfections or quality of biopsy. Liedo et al. [25] did
comparison of pregnancy outcomes after transfers of euploid and
mosaic embryos and concluded that after adding embryo quality
as a confounding factor, miscarriage rate differences were not sig-
nificant. Chuang et al. [26] compared chromosomal constitutions
between different TE biopsy sites and TE and ICM. The distance
from ICM does not have an impact on chromosomal consistency
(TE site 1 – 86.2% and TE site 2 – 89.7%), pointing that aberrant
cells spread randomly in the embryo. The level of confined mosai-
cism observed was 14%.
Conclusion
In this article, we reviewed the pregnancy outcomes of mosaic
embryo transfers regarding embryo quality, maternal age, genetic
testing approach used, and recognition of artifacts. Our results
and suggestions are concordant with other studies – implantation
rates are lower after mosaic embryo transfers, however, such
results should not be a crucial factor for avoiding the transfer.
Artifacts have to be differentiated from undeniable aberrations
and correct interpretation of results must be done. It is advisable
to avoid transfer with embryos with mosaic aneuploidies, which
are viable with congenital anomalies. Transfers of mosaic
embryos should be considered more carefully and must include
patient counseling and following prenatal testing if necessary.
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